The U.S. molecular biology enzymes, reagents, and kits market size was estimated at USD 520.00 million in 2025 and is projected to be worth around USD 1,242.37 million by 2035, is expanding at a CAGR of 9.10% from 2026 to 2035. The growing prevalence of chronic diseases, the growing demand for inclusion of advanced technologies, and the higher demand for diagnostic tools, altogether help to fuel the growth of the market.

U.S. Molecular Biology Enzymes Reagents and Kits Market Statical Scope

The U.S. molecular biology enzymes, reagents, and kits market is also dominating with the help of factors such as investments in PCR technology, next-generation sequencing, and personalized medicine . Growing demand for diagnostic kits and reagents to treat the prevalence of chronic diseases is one of the vital factors for the growth of the market. Propelling research funding and growing R&D expenditures are helping to fuel the market's growth.

U.S. Molecular Biology Enzymes, Reagents, and Kits Market, By Product, 2025

• Kits and Reagents- The segment dominated the global market with 68% of the market share. Growing demand for PCR sequencing and sample preparation tools is a major factor fueling the segment's demand. Growing need for high-throughput and consistent results, along with the propelling demand for PCR kits, sequencing reagents, and cloning kits, also helps to fuel the market's growth.
• Enzymes- The segment accounts for 32% of the market share due to growing demand for specialized tools in diagnostics and research. Growing demand for high-performance and customized enzymes also helps to propel the market's growth. Growing adoption of precision medicine and increased federal research funding also help to fuel the growth of the market.

U.S. Molecular Biology Enzymes, Reagents, and Kits Market, By Application, 2025

• PCR- The segment dominated the market with 10% of the market share in 2025 and is driven by factors such as the major prevalence of chronic diseases leading to higher demand for diagnostic testing. Growing demand for personalized medicine initiatives, significant R&D investments in the pharma and biotechnology sectors, also fuel the growth of the market.
• Sequencing- The segment holds 15% of the market share and is mainly propelled by factors such as NGS and high-throughput workflows. DNA and RNA sequencing also help to fuel the growth of the market. The segment also focuses on optimized library preparation, further fueling the market's growth.

U.S. Molecular Biology Enzymes, Reagents, and Kits Market, By End Use, 2025

• Pharma and Biotech- The segment dominated the market with 46% of the market share, with growing demand for genomic research, precision medicine, and diagnostic tools. Growing investments in R&D for drug discovery and therapeutic development also help to fuel the growth of the market.
• Academic and Research- The segment accounts for 31% of the market share and is majorly driven by growing investments in research funding, genomic studies, and high-throughput sequencing. Growing investments in academic life science research and genomics also help to fuel the growth of the segment.

Top Companies in the U.S. Molecular Biology Enzymes, Reagents, and Kits Market

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Agilent Technologies, Inc.
• QIAGEN
• Promega Corporation
• New England Biolabs
• Merck KGaA
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories, Inc.
• Takara Bio, Inc.
• LGC Limited

Segments Covered in the Report

By Product

• Kits and Reagents
• Enzymes

By Application

• PCR
• Sequencing
• Cloning
• Epigenetics
• Genotyping
• RCA/MDA
• RNA Therapeutics
• Transcriptomics
• Proteomics
• Liquid Biopsy
• Other Applications

By End-use

• Pharma & Biotech
• Academic & Research
• Hospital & Diagnostics
• Others